Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Tuninetti V, Pace L, Ghisoni E, Quarà V, Arezzo F, Palicelli A, Mandato VD, Geuna E, Cormio G, Biglia N, Borsotti L, Gallo S, Ferrero A, Jacomuzzi E, Fuso L, Pezua Sanjinez JOS, Puppo A, Caglio A, Rognone C, Turinetto M, Scotto G, Di Maio M, Valabrega G. Tuninetti V, et al. Among authors: borsotti l. Cancers (Basel). 2023 Jul 15;15(14):3639. doi: 10.3390/cancers15143639. Cancers (Basel). 2023. PMID: 37509300 Free PMC article.
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, Maldi E, Artioli G, Mammoliti S, Zanchi L, Sikokis A, Biglia N, Parisi A, Mandato VD, Carella C, Cormio G, Marinaccio M, Puppo A, Paolini B, Borsotti L, Scotto G, Turinetto M, Sangiolo D, Di Maio M, Valabrega G. Tuninetti V, et al. Among authors: borsotti l. Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032. Cancers (Basel). 2023. PMID: 36831376 Free PMC article.
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, Mantiero M, Azzolina C, Geninatti E, Pignata S, Valabrega G. Tuninetti V, et al. Among authors: borsotti l. Eur J Cancer. 2024 Mar 30;203:114039. doi: 10.1016/j.ejca.2024.114039. Online ahead of print. Eur J Cancer. 2024. PMID: 38598922